Stocks · News reference
Oppenheimer analyst Leland Gershell reiterates OnKure Therapeutics (NASDAQ:OKUR) with a Outperform and lowers the price target from $30 to $14.
Reference Details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
OnKure Therapeutics announced that senior management will participate in the Morgan Stanley 24th Annual Global Healthcare Conference on September 14-16, 2026, in New York. The company will host one-on-one investor meetings during the event. OnKure is advancing IND-enabling activities for next-generation PI3Kα inhibitor candidates OKI-345 and OKI-355, with IND submissions planned for the first half of 2027.
Filed: 2026-08-13 AccNo: 0001193125-26-347315 Size: 158 KB Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers Item 9.01: Financial Statements and Exhibits
OnKure Therapeutics (NASDAQ:OKUR) reported quarterly losses of $(0.31) per share which beat the analyst consensus estimate of $(0.54) by 41.51 percent. This is a 72.81 percent increase over losses of $(1.14) per share